Leerink Partners Believes Affimed (NASDAQ: AFMD) Still Has Room to Grow

In a report issued on April 9, Daina Graybosch from Leerink Partners reiterated a Buy rating on Affimed (AFMDResearch Report). The company’s shares closed last Monday at $9.65, close to its 52-week high of $10.70.

According to TipRanks.com, Graybosch is a 4-star analyst with an average return of 17.6% and a 43.6% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Silverback Therapeutics, Molecular Partners AG, and Bolt Biotherapeutics.

Affimed has an analyst consensus of Strong Buy, with a price target consensus of $14.00, representing a 45.1% upside. In a report issued on March 30, Credit Suisse also initiated coverage with a Buy rating on the stock with a $15.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $10.70 and a one-year low of $1.88. Currently, Affimed has an average volume of 3.23M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.